Abstract
This post hoc analysis of a 7-week, randomized, double-blind trial evaluated the efficacy and safety of initial irbesartan/hydrochlorothiazide treatment in 468 patients with severe, uncontrolled, hypertension (diastolic blood pressure [DBP] > or =100 mm Hg) at high cardiovascular risk. Systolic blood pressure (SBP)/DBP reductions ranged from 28.0 to 42.9/22.9 to 27.2 mm Hg in patients with obesity, diabetes, baseline SBP > or =180 mm Hg, and in the elderly. Blood pressure control to <140/90 mm Hg in the age and obesity subgroups ranged from 32.1% to 39.2% while control to <130/80 mm Hg in patients with diabetes was 11.5%. After 1 week of therapy, 72.5% of patients no longer had SBP > or =180 mm Hg; by 7 weeks, 51.3% had SBP 140 to 159 mm Hg and 26.5% had SBP <140 mm Hg. Treatment was well tolerated regardless of the subgroup. No excess of prespecified events was noted. Thus, initial treatment with irbesartan/hydrochlorothiazide was rapidly effective in high-risk, difficult-to-treat, severely hypertensive patients.
References
Nov 25, 1978·Lancet·T W Anderson
Dec 11, 1967·JAMA : the Journal of the American Medical Association
Jan 1, 1996·Hypertension·B ZampaglioneP Cavallo-Perin
Sep 11, 1998·BMJ : British Medical Journal
Dec 31, 1998·The New England Journal of Medicine·D R BerlowitzM A Moskowitz
Aug 11, 2000·BMJ : British Medical Journal·A I AdlerR R Holman
Sep 6, 2000·Lancet·M J BrownL M Ruilope
Sep 22, 2001·The New England Journal of Medicine·H H ParvingUNKNOWN Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
Aug 13, 2002·Journal of Hypertension·Giuseppe Mancia, Guido Grassi
Oct 29, 2002·Diabetes Care·Ferdinando C SassoDomenico Cozzolino
Dec 21, 2002·Lancet·Sarah LewingtonUNKNOWN Prospective Studies Collaboration
May 16, 2003·JAMA : the Journal of the American Medical Association·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Jun 23, 2004·Lancet·Michael A WeberAlberto Zanchetti
Oct 7, 2004·Current Medical Research and Opinion·P BramlageW Kirch
Dec 23, 2004·Kidney International. Supplement·Fernando de AlvaroUNKNOWN KORAL HT Investigators
Dec 23, 2004·Journal of Hypertension·Jean-Jacques MouradUNKNOWN investigators of the STRATHE trial
Jul 5, 2005·Expert Opinion on Investigational Drugs·C I Johnston
Aug 27, 2005·Journal of the American Society of Nephrology : JASN·Marc A PohlEdmund J Lewis
Oct 18, 2005·The Journal of Clinical Hypertension·Joel M NeutelUNKNOWN INCLUSIVE Investigators
Feb 24, 2006·Blood Pressure·Olivier RouxJacques Blacher
Jul 20, 2006·The Journal of Clinical Hypertension·James R SowersUNKNOWN INCLUSIVE Investigators
Dec 16, 2006·The Journal of Clinical Hypertension·Joel M NeutelPablo Lapuerta
May 30, 2007·Clinical Drug Investigation·Arya M SharmaWilhelm Kirch
Jun 15, 2007·Journal of Hypertension·Giuseppe ManciaUNKNOWN European Society of Cardiology
Dec 6, 2007·The Journal of Clinical Hypertension·Matthew R WeirPablo Lapuerta
Jan 5, 2008·The American Journal of Geriatric Cardiology·William C CushmanMichael A Weber
May 7, 2008·Archives of Gerontology and Geriatrics·Roberto FogariGiuseppe Derosa
Citations
Sep 29, 2011·Integrated Blood Pressure Control·Valentina ForniMichel Burnier
Oct 15, 2013·Vascular Health and Risk Management·Fotini Gialama, Nikos Maniadakis
Mar 8, 2016·Journal of the American Society of Hypertension : JASH·Fatai Adesina MarufJoshua Odunayo Akinyemi
Mar 1, 2019·Circulation·Melissa S Burroughs PeñaMichelle A Albert